Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer in Europe, North America, Asia, and internationally. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer using its proprietary DNA methylation biomarker, Septin9. The company also offers Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool provides set of reagents for the preparation of bisulfite-converted DNA. Its development pipeline also contains products for screening, early detection, and diagnosis of colorectal and lung cancers. In addition, the company engages in the research and identification of additional DNA methylation biomarkers for prostate, bladder, breast, and ovarian cancers. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.
Industry, Sector and Symbol
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone49 30 243 450
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees43
Next Earnings DateN/A
OptionableNot Optionable
EPIGENOMICS AG/S (OTCMKTS:EPGNY) Frequently Asked Questions
What is EPIGENOMICS AG/S's stock symbol?
EPIGENOMICS AG/S trades on the OTCMKTS under the ticker symbol "EPGNY."
Has EPIGENOMICS AG/S been receiving favorable news coverage?
News headlines about EPGNY stock have trended somewhat positive on Friday, InfoTrie reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. EPIGENOMICS AG/S earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for EPIGENOMICS AG/S.
Who are some of EPIGENOMICS AG/S's key competitors?
What other stocks do shareholders of EPIGENOMICS AG/S own?
Who are EPIGENOMICS AG/S's key executives?
EPIGENOMICS AG/S's management team includes the folowing people:
- Mr. Gregory Hamilton, CEO & Member of Exec. Board (Age 49)
- Dr. Helge Lubenow, Member of Supervisory Board
- Dr. Jorge A. Garces, Pres, Chief Scientific Officer & Member of the Exec. Board (Age 47)
- Mr. Albert Weber, Exec. VP of Fin. (Age 56)
- Mr. Peter Vogt, VP of Corp. Communications & Investor Relations
How do I buy shares of EPIGENOMICS AG/S?
Shares of EPGNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is EPIGENOMICS AG/S's stock price today?
One share of EPGNY stock can currently be purchased for approximately $6.80.
What is EPIGENOMICS AG/S's official website?
How can I contact EPIGENOMICS AG/S?
The company can be reached via phone at 49 30 243 450.
MarketBeat Community Rating for EPIGENOMICS AG/S (OTCMKTS EPGNY)
MarketBeat's community ratings are surveys of what our community members think about EPIGENOMICS AG/S and other stocks. Vote "Outperform" if you believe EPGNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPGNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
